Search research articles
Contact Us
Filters
Showing results (221-230 of 237) with videos related to
Page
of 24
Sort By:
Molecular Medicine (Cambridge, Mass.)
|
September 29, 2011
Torque teno virus 10 isolated by genome amplification techniques from a patient with concomitant chronic lymphocytic leukemia and polycythemia vera
Charles C Chu, Lu Zhang, Arjun Dhayalan, et al.
Blood Advances
|
August 16, 2022
Efficacy comparison of tisagenlecleucel vs usual care in patients with relapsed or refractory follicular lymphoma
Gilles Salles, Stephen J Schuster, Martin Dreyling, et al.
Haematologica
|
April 4, 2024
Outcomes after chimeric antigen receptor T-cell therapy across large B-cell lymphoma subtypes
Christianne Bourlon, Claire Roddie, Tobias Menne, et al.
British Journal of Haematology
|
February 16, 2019
Efficacy of venetoclax monotherapy in patients with relapsed chronic lymphocytic leukaemia in the post-BCR inhibitor setting: a UK wide analysis
Toby A Eyre, Amy A Kirkwood, Sat Gohill, et al.
British Journal of Haematology
|
March 30, 2026
Patient-reported health-related quality of life in previously untreated chronic lymphocytic leukaemia: Results from the randomised phase 3 FLAIR trial comparing ibrutinib-rituximab versus fludarabine-cyclophosphamide-rituximab
David J Allsup, David A Cairns, E Faye Samy, et al.
Blood
|
October 7, 2020
Triggering interferon signaling in T cells with avadomide sensitizes CLL to anti-PD-L1/PD-1 immunotherapy
Nikolaos Ioannou, Patrick R Hagner, Matt Stokes, et al.
Cancer Cell
|
October 22, 2021
Humoral and cellular immunity to delayed second dose of SARS-CoV-2 BNT162b2 mRNA vaccination in patients with cancer
Duncan R McKenzie, Miguel Muñoz-Ruiz, Leticia Monin, et al.
The Lancet. Haematology
|
April 2, 2025
A 3-week pause versus continued Bruton tyrosine kinase inhibitor use during COVID-19 vaccination in individuals with chronic lymphocytic leukaemia (IMPROVE trial): a randomised, open-label, superiority trial
Jonathan A Cook, Piers E M Patten, Nicholas Peckham, et al.
The Lancet. Oncology
|
May 4, 2023
Ibrutinib and rituximab versus fludarabine, cyclophosphamide, and rituximab for patients with previously untreated chronic lymphocytic leukaemia (FLAIR): interim analysis of a multicentre, open-label, randomised, phase 3 trial
Peter Hillmen, Alexandra Pitchford, Adrian Bloor, et al.
The New England Journal of Medicine
|
December 11, 2023
Chronic Lymphocytic Leukemia Therapy Guided by Measurable Residual Disease
Talha Munir, David A Cairns, Adrian Bloor, et al.
Page
of 24
Search research articles
Search
Showing results (221-230 of 237) with videos related to
Sort By:
Page
of 24
Molecular Medicine (Cambridge, Mass.)
|
September 29, 2011
Torque teno virus 10 isolated by genome amplification techniques from a patient with concomitant chronic lymphocytic leukemia and polycythemia vera
Charles C Chu, Lu Zhang, Arjun Dhayalan, et al.
Blood Advances
|
August 16, 2022
Efficacy comparison of tisagenlecleucel vs usual care in patients with relapsed or refractory follicular lymphoma
Gilles Salles, Stephen J Schuster, Martin Dreyling, et al.
Haematologica
|
April 4, 2024
Outcomes after chimeric antigen receptor T-cell therapy across large B-cell lymphoma subtypes
Christianne Bourlon, Claire Roddie, Tobias Menne, et al.
British Journal of Haematology
|
February 16, 2019
Efficacy of venetoclax monotherapy in patients with relapsed chronic lymphocytic leukaemia in the post-BCR inhibitor setting: a UK wide analysis
Toby A Eyre, Amy A Kirkwood, Sat Gohill, et al.
British Journal of Haematology
|
March 30, 2026
Patient-reported health-related quality of life in previously untreated chronic lymphocytic leukaemia: Results from the randomised phase 3 FLAIR trial comparing ibrutinib-rituximab versus fludarabine-cyclophosphamide-rituximab
David J Allsup, David A Cairns, E Faye Samy, et al.
Blood
|
October 7, 2020
Triggering interferon signaling in T cells with avadomide sensitizes CLL to anti-PD-L1/PD-1 immunotherapy
Nikolaos Ioannou, Patrick R Hagner, Matt Stokes, et al.
Cancer Cell
|
October 22, 2021
Humoral and cellular immunity to delayed second dose of SARS-CoV-2 BNT162b2 mRNA vaccination in patients with cancer
Duncan R McKenzie, Miguel Muñoz-Ruiz, Leticia Monin, et al.
The Lancet. Haematology
|
April 2, 2025
A 3-week pause versus continued Bruton tyrosine kinase inhibitor use during COVID-19 vaccination in individuals with chronic lymphocytic leukaemia (IMPROVE trial): a randomised, open-label, superiority trial
Jonathan A Cook, Piers E M Patten, Nicholas Peckham, et al.
The Lancet. Oncology
|
May 4, 2023
Ibrutinib and rituximab versus fludarabine, cyclophosphamide, and rituximab for patients with previously untreated chronic lymphocytic leukaemia (FLAIR): interim analysis of a multicentre, open-label, randomised, phase 3 trial
Peter Hillmen, Alexandra Pitchford, Adrian Bloor, et al.
The New England Journal of Medicine
|
December 11, 2023
Chronic Lymphocytic Leukemia Therapy Guided by Measurable Residual Disease
Talha Munir, David A Cairns, Adrian Bloor, et al.
Page
of 24